

I support the proposal. As the outlier costs of some pharmaceuticals increases, it decreases the ability to address broader improvements for more Oregonian's health. The assertion that innovation will be stifled is misleading and largely unsubstantiated. Having a transparent discussion leads to good public policy, that's nothing to be afraid of.  
Charles Gallia, PhD.